Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse til forebyggelse af kronificeringsmigræne gennem forudsigelse af respons på behandling med anti-CGRP-antistoffer (PREDI-CGRP)

Forudsigelsesundersøgelse eller respons på behandling med anti-CGRP monoklonale antistoffer i migræne

Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Detaljeret beskrivelse

The study consists of an initial visit coinciding with the start of treatment, a subsequent visit after 6 months of treatment and finally another after 12 months, coinciding with the end of treatment. In case of worsening after suspension, a clinical visit will be carried out at the time of worsening to evaluate the reintroduction of the drug and in case of reintroduction, a visit will be carried out after 3 months. If patients do not worsen, a visit will be made 6 months after completing treatment.

At each visit, demographic and clinical variables will be collected. In addition, 3 blood tests will be performed corresponding to the beginning of treatment, after 6 months and a month and a half from the last infiltration. Likewise, a brain MRI will be obtained prior to the start of treatment. These blood samples and neuroimaging data will be processed for subsequent analysis.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

350

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Aragon
      • Zaragoza, Aragon, Spanien, 50009
        • Hospital Clínico Universitario Lozano Blesa
    • Basque Country
      • Donostia / San Sebastian, Basque Country, Spanien, 20014
        • Hospital Universitario Donostia
    • Cantabria
      • Santander, Cantabria, Spanien, 39008
        • Hospital Universitario Marqués de Valdecilla
    • Castille and León
      • Valladolid, Castille and León, Spanien, 47010
        • Hospital Clínico Universitario de Valladolid
    • Catalonia
      • Barcelona, Catalonia, Spanien, 08035
        • Hospital Universitari Vall d'Hebron Research Institute
    • Madrid
      • Madrid, Madrid, Spanien, 28006
        • Hospital Universitario de La Princesa
    • Valencia
      • Valencia, Valencia, Spanien, 46026
        • Hospital Universitario Politécnico La Fe

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients aged between 18 and 65 years with a diagnosis of episodic or chronic migraine who, at the discretion of their neurologist and according to clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or its receptor (Erenumab) be included. These patients will come from 7 Headache Units in Spain belonging to the following hospitals:

  • La Princesa University Hospital
  • Vall d'Hebron University Hospital
  • Marqués de Valdecilla University Hospital
  • Valladolid University Clinical Hospital
  • Donostia University Hospital
  • Lozano Blesa University Clinical Hospital
  • La Fe Polytechnic University Hospital

Beskrivelse

Inclusion Criteria:

  • Patients aged between 18 and 65 years.
  • Caucasian ethnicity.
  • Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
  • Have at least one year of history of migraine.
  • Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.
  • Patients able to describe their clinical situation and the characteristics of their headache.
  • Grant your informed consent.

Exclusion Criteria:

  • Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
  • Neurological focus in the examination.
  • Pregnancy or breastfeeding period.
  • Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.
  • Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.
  • Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Patients with migraine under treatment with monoclonal antibodies against CGRP

Patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or else its receptor (Erenumab) will be included.

The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication.

Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia.

Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Biomarkers of positive initial response to monoclonal antibodies
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

Establish clinical, demographic, transcriptomic, genetic, molecular and/or radiological characteristics that allow predicting a positive initial response to monoclonal antibodies (biomarkers of therapeutic response).

From the beginning of treatment, which is the initial visit, to 18 months of follow-up

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sustained response factors
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

To analyze sustained response factors at the sociodemographic, clinical, transcriptomic, genetic, molecular and/or radiological level after the suspension of anti-CGRP drugs.

From the beginning of treatment, which is the initial visit, to 18 months of follow-up
Sustained response after discontinuation of the anti-CGRP antibody
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

To quantify the proportion of patients who present a sustained response after discontinuation of the anti-CGRP antibody.

From the beginning of treatment, which is the initial visit, to 18 months of follow-up
Non-maintained pharmacological response relation with biomarkers
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

To characterize whether the non-maintained pharmacological response is related to the variables previously characterized as predictors of chronicity.

From the beginning of treatment, which is the initial visit, to 18 months of follow-up
Time until relapse after discontinuation of the anti-CGRP antibody
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

To determine the time until relapse after discontinuation of the anti-CGRP monoclonal antibody in those patients who, having presented a positive initial response, discontinue it.

From the beginning of treatment, which is the initial visit, to 18 months of follow-up
Biomarkers of patients with high-frequency episodic migraine and chronic migraine
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up

To validate possible transcriptomic, genetic, molecular and/or radiological characteristics that allow differentiation between patients with high-frequency episodic migraine and chronic migraine in a national multicenter cohort.

From the beginning of treatment, which is the initial visit, to 18 months of follow-up

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Ana Beatriz Gago Veiga, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. april 2023

Primær færdiggørelse (Faktiske)

31. juli 2026

Studieafslutning (Anslået)

1. december 2026

Datoer for studieregistrering

Først indsendt

5. juni 2024

Først indsendt, der opfyldte QC-kriterier

10. juni 2024

Først opslået (Faktiske)

14. juni 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. januar 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared with other researchers. This decision is based on data protection and confidentiality requirements in accordance with applicable European and national regulations (including GDPR). Given that this is a multicentre observational study conducted in routine clinical practice, access to IPD is restricted to the study investigators for the purposes of the predefined analyses.

Any potential secondary use of the dataset would only be considered in fully anonymized form and subject to prior ethical approval and compliance with applicable data protection legislation.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner